Meeting News

CLS-TA improves inflammation in anterior uveitis

SAN FRANCISCO — Patients with anterior uveitis treated with suprachoroidal corticosteroid triamcinolone acetonide achieved resolution of anterior chamber cells and showed improvements in visual acuity, according to a study presented at the American Academy of Ophthalmology annual meeting.

“Despite appropriate control and resolution of inflammation, many patients with uveitis have continued cystoid macular edema, which requires treatment with steroids,” Ashleigh Laurin Levison, MD, of Kaiser Permanente, told Ocular Surgery News. “Many of the available treatments are not approved for use in patients who only have anterior uveitis.”

Levison conducted a post hoc subgroup analysis of the phase 3 PEACHTREE trial to evaluate the efficacy of suprachoroidal (SC) corticosteroid triamcinolone acetonide (CLS-TA, Clearside Biomedical) for anterior uveitis.

Researchers randomly assigned 160 patients with uveitis from any anatomic location to receive SC CLS-TA or sham at day 0 and week 12 at a ratio of 3:2. Follow-up was conducted at week 24. About of quarter of participants had anterior uveitis.

At week 24, data indicated that patients treated with SC CLS-TA had greater improvements in best corrected visual acuity letter gain (14.4 vs. 2.9 letters) and central subfield thickness (120.9 vs. 50.4 microns). Additionally, more patients in the SC CLS-TA group showed resolution of anterior chamber cells than those in the sham group (74% vs. 50%) by the end of follow-up.

Rescue therapy was needed in many more patients treated with sham.

Of the five patients with a 2+ or greater score of anterior chamber cells at day 0, four were in the CLS-TA group and reached resolution as early as week 4 and maintained through the end of the study.

Investigators did not observe any major safety concerns associated with CLS-TA.

“While numbers were small for those with anterior uveitis, CLS-TA worked very well to treat cystoid macular edema and resolve anterior chamber cell in patients with anterior uveitis,” Levison said.

“If FDA approved, this would be a great option for treatment of cystoid macular edema in patients with anterior uveitis,” she added. – by Alaina Tedesco

Reference: Levison AL. A subgroup analysis of subjects diagnosed with anterior uveitis from the phase 3 PEACHTREE clinical trial. Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Levison reports receiving honoraria from AbbVie and being a consultant for Clearside Biomedical and Santen Inc.

SAN FRANCISCO — Patients with anterior uveitis treated with suprachoroidal corticosteroid triamcinolone acetonide achieved resolution of anterior chamber cells and showed improvements in visual acuity, according to a study presented at the American Academy of Ophthalmology annual meeting.

“Despite appropriate control and resolution of inflammation, many patients with uveitis have continued cystoid macular edema, which requires treatment with steroids,” Ashleigh Laurin Levison, MD, of Kaiser Permanente, told Ocular Surgery News. “Many of the available treatments are not approved for use in patients who only have anterior uveitis.”

Levison conducted a post hoc subgroup analysis of the phase 3 PEACHTREE trial to evaluate the efficacy of suprachoroidal (SC) corticosteroid triamcinolone acetonide (CLS-TA, Clearside Biomedical) for anterior uveitis.

Researchers randomly assigned 160 patients with uveitis from any anatomic location to receive SC CLS-TA or sham at day 0 and week 12 at a ratio of 3:2. Follow-up was conducted at week 24. About of quarter of participants had anterior uveitis.

At week 24, data indicated that patients treated with SC CLS-TA had greater improvements in best corrected visual acuity letter gain (14.4 vs. 2.9 letters) and central subfield thickness (120.9 vs. 50.4 microns). Additionally, more patients in the SC CLS-TA group showed resolution of anterior chamber cells than those in the sham group (74% vs. 50%) by the end of follow-up.

Rescue therapy was needed in many more patients treated with sham.

Of the five patients with a 2+ or greater score of anterior chamber cells at day 0, four were in the CLS-TA group and reached resolution as early as week 4 and maintained through the end of the study.

Investigators did not observe any major safety concerns associated with CLS-TA.

“While numbers were small for those with anterior uveitis, CLS-TA worked very well to treat cystoid macular edema and resolve anterior chamber cell in patients with anterior uveitis,” Levison said.

“If FDA approved, this would be a great option for treatment of cystoid macular edema in patients with anterior uveitis,” she added. – by Alaina Tedesco

Reference: Levison AL. A subgroup analysis of subjects diagnosed with anterior uveitis from the phase 3 PEACHTREE clinical trial. Presented at: American Academy of Ophthalmology annual meeting; Oct. 11-15, 2019; San Francisco.

Disclosure: Levison reports receiving honoraria from AbbVie and being a consultant for Clearside Biomedical and Santen Inc.

    See more from Discoveries from AAO: Pain and Inflammation